이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RaySearch Laboratories 관리

관리 기준 확인 3/4

RaySearch Laboratories' CEO는 Johan Lof, Jan2000 에 임명되었습니다 의 임기는 24.42 년입니다. 총 연간 보상은 SEK 9.76M, 66.2% 로 구성됩니다. 66.2% 급여 및 33.8% 보너스(회사 주식 및 옵션 포함). 는 € 68.25M 가치에 해당하는 회사 주식의 16.51% 직접 소유합니다. 68.25M. 경영진과 이사회의 평균 재임 기간은 각각 5.7 년과 20.8 년입니다.

주요 정보

Johan Lof

최고 경영자

SEK 9.8m

총 보상

CEO 급여 비율	66.2%
CEO 임기	24.4yrs
CEO 소유권	16.5%
경영진 평균 재임 기간	5.7yrs
이사회 평균 재임 기간	20.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Johan Lof 의 보수는 RaySearch Laboratories 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	SEK 101m
Dec 31 2023	SEK 10m	SEK 6m	SEK 82m
Sep 30 2023	n/a	n/a	SEK 64m
Jun 30 2023	n/a	n/a	SEK 53m
Mar 31 2023	n/a	n/a	SEK 22m
Dec 31 2022	SEK 7m	SEK 6m	SEK 24m
Sep 30 2022	n/a	n/a	-SEK 6m
Jun 30 2022	n/a	n/a	-SEK 38m
Mar 31 2022	n/a	n/a	-SEK 35m
Dec 31 2021	SEK 7m	SEK 6m	-SEK 47m
Sep 30 2021	n/a	n/a	-SEK 46m
Jun 30 2021	n/a	n/a	-SEK 50m
Mar 31 2021	n/a	n/a	-SEK 42m
Dec 31 2020	SEK 7m	SEK 6m	-SEK 9m
Sep 30 2020	n/a	n/a	SEK 24m
Jun 30 2020	n/a	n/a	SEK 43m
Mar 31 2020	n/a	n/a	SEK 74m
Dec 31 2019	SEK 8m	SEK 6m	SEK 50m
Sep 30 2019	n/a	n/a	SEK 64m
Jun 30 2019	n/a	n/a	SEK 85m
Mar 31 2019	n/a	n/a	SEK 84m
Dec 31 2018	SEK 8m	SEK 5m	SEK 79m
Sep 30 2018	n/a	n/a	SEK 118m
Jun 30 2018	n/a	n/a	SEK 104m
Mar 31 2018	n/a	n/a	SEK 103m
Dec 31 2017	SEK 9m	SEK 5m	SEK 118m

보상 대 시장: Johan 의 총 보상 ($USD 934.99K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.06M ).

보상과 수익: Johan 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Johan Lof (55 yo)

24.4yrs

테뉴어

SEK 9,758,000

보상

Dr. Johan Lof has been the Chief Executive Officer and President of Raysearch Laboratories AB (Publ) since 2000. Dr. Lof serves as the Chief Executive Officer of RaySearch Medical AB. Dr. Lof has been a Di...

리더십 팀

이름	위치	테뉴어	보상	소유권
Johan Lof	Founder	24.4yrs	SEK 9.76m	16.51% SEK 70.5m
Bjorn Hardemark	Deputy Chief Executive Officer	8.8yrs	SEK 3.54m	0.052% SEK 224.2k
Annika Henriksson	Deputy Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Kjell Eriksson	Head of Research & Chief Science Officer	8.8yrs	데이터 없음	0.070% SEK 299.0k
Petra Jansson	General Counsel	6.9yrs	데이터 없음	데이터 없음
Peter Kemlin	Director of Sales & Marketing	no data	데이터 없음	0.0041% SEK 17.4k
Tove Alteborg	Global Human Resource Manager	less than a year	데이터 없음	데이터 없음
Fredrik Lofman	Head of Machine Learning	4.4yrs	데이터 없음	0.0041% SEK 17.4k
Marc Mlyn	President & CEO of RaySearch Americas	2.4yrs	데이터 없음	데이터 없음

5.7yrs

평균 재임 기간

50.5yo

평균 연령

경험이 풍부한 관리: 27R 의 관리팀은 노련하고 경험 (평균 재직 기간 5.7 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Johan Lof	Founder	24.4yrs	SEK 9.76m	16.51% SEK 70.5m
Hans Wigzell	Independent Chairman of Board	20.1yrs	SEK 840.00k	데이터 없음
Carl Bergendal	Independent Director	24.4yrs	SEK 225.00k	3.39% SEK 14.5m
Radhe Mohan	Member of Scientific Advisory Board	21.4yrs	데이터 없음	데이터 없음
Anders Forsgren	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Anders Brahme	Member of Scientific Advisory Board	no data	데이터 없음	3.79% SEK 16.2m
David Jaffray	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Britta Wallgren	Independent Director	6.1yrs	SEK 300.00k	0.020% SEK 87.2k
Gunther Marder	Independent Director	1.6yrs	SEK 300.00k	0.20% SEK 871.4k

20.8yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: 27R 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 20.8 년).

RaySearch Laboratories 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold €3.4m worth of stock

Founder recently sold €94k worth of stock

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

Recent updates

RaySearch Laboratories AB (publ) Releases RayCare 2024A

Now 22% undervalued

Raysearch Laboratories AB (Publ) Apprves Ordinary Dividend for the Year 2023

First quarter 2024 earnings released: EPS: kr1.07 (vs kr0.51 in 1Q 2023)

Raysearch to Present the Latest Advances in Raystation, Raycare and Rayintelligence At Estro 2024

Full year 2023 earnings released: EPS: kr2.38 (vs kr0.69 in FY 2022)

New major risk - Revenue and earnings growth

RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

RaySearch Laboratories AB (publ) Releases Raystation 2024A

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023

RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2023 earnings released: EPS: kr0.32 (vs kr0.58 loss in 2Q 2022)

RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024

RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023

RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System

New minor risk - Share price stability

RaySearch Laboratories AB (publ) Releases Raystation 2023B

Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Henrik Bergentoft Leaves the Position as CFO for Raysearch

New minor risk - Insider selling

Founder recently sold €3.4m worth of stock

New minor risk - Shareholder dilution

RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023

First quarter 2023 earnings released

Founder recently sold €94k worth of stock

Full year 2022 earnings released: EPS: kr0.69 (vs kr1.38 loss in FY 2021)

RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Third quarter 2022 earnings released

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Second quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

RaySearch Laboratories AB (publ) Launches RayStation 12A

RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022

RaySearch Laboratories AB (publ) Releases Latest Version of RayCare

Founder recently sold €1.9m worth of stock

First quarter 2022 earnings released

Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022

Insufficient new directors

RaySearch Laboratories AB (publ) Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Founder recently sold €550k worth of stock

RaySearch AB (publ) Provides Cancer Clinics with User Configurable Workflows for Radiation Therapy

RayStation 11B Brings New Features for Adaptive Workflows, Brachytherapy, and Radiation Therapy with Ions

Third quarter 2021 earnings released

RaySearch Laboratories AB (publ) to Showcase Latest Innovations, RayIntelligence and RayCare at ESTRO 2021

Second quarter 2021 earnings released

Insufficient new directors

RaySearch Laboratories AB (Publ) Announces RayStation 9 Granted Regulatory Clearance in China

Raysearch Announces the Release of A New Version of Raycare®, the Next-Generation Oncology Information System

Raysearch Laboratories Announces the Release of Raystation® 11A

Raysearch Laboratories AB (Publ) Provides Earnings Guidance for 2021

RaySearch Laboratories AB (publ) Announces Royal Brisbane and Women's Hospital Treats First Patients Using the Raystation® Treatment Planning System

Full year 2020 earnings released: kr0.26 loss per share (vs kr1.47 profit in FY 2019)

Revenue misses expectations

RaySearch Laboratories AB (publ) to Report First Half, 2021 Results on Aug 25, 2021

New 90-day high: €9.09

RaySearch Laboratories AB (publ) Announces University Medical Center Maribor in Slovenia Became the 700th Customer to Select RayStation

New 90-day high: €8.92

RaySearch Receives New Order from Centre Antoine Lacassagne for RayStation in France

RaySearch Laboratories AB (Publ) Announces the Release of the First Version of the Treatment Control System (TCS) Raycommand

RaySearch Laboratories AB (publ) Announces Expansion of the Advanced Treatment Planning System Raystation

New 90-day high: €8.35